Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer

(2020) Glenn J. Hanna et al.   CANCER

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

(2020) Mara Gilardi et al.   MOLECULAR CANCER THERAPEUTICS

The changing therapeutic landscape of head and neck cancer

(2019) John D. Cramer et al.   Nature Reviews Clinical Oncology

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

(2019) Ezra E. W. Cohen et al.   Journal for ImmunoTherapy of Cancer

Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy

(2019) Madison Canning et al.   Frontiers in Cell and Developmental Biology

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers

(2018) Brian R. Untch et al.   CANCER RESEARCH

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

(2018) R Galot et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Treating head and neck cancer: for better or for worse?

(2017) Alex Sklan et al.   LANCET ONCOLOGY

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

(2016) Beth O. Van Emburgh et al.   Nature Communications

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma

(2016) Friederike Braig et al.   Oncotarget

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact

(2014) G. Mountzios et al.   ANNALS OF ONCOLOGY

SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury

(2014) L. M. Niswander et al.   BLOOD

RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

(2014) T. Rampias et al.   CLINICAL CANCER RESEARCH

Regulation of Circulating Neutrophil Numbers under Homeostasis and in Disease

(2013) Natasha Strydom et al.   Journal of Innate Immunity

Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

(2013) C. R. Pickering et al.   Cancer Discovery

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

In-Hospital Mortality in Patients Older Than 60 Years with Very Low Albumin Levels

(2011) Jodi L. Hannan et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

(2011) M H Kirschbaum et al.   LEUKEMIA

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE